GenAI is on the precipice of breaking new ground in regulatory intelligence; making strategists more efficient by alleviating challenges, streamlining regulatory research and submission processes.
at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?
The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.
Top industry experts weigh in on what the new year holds for the pharma industry.
New regulations may require regulators to explore new payment options.
Precision & Specialty Medicines are driving changes in the pharma development industry. We explore the changes these paradigms are having on the clinical trial space.
Significant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.
Exploring the importance of analytics as a means of staying competitive in the commercial pharmaceutical market.
MIDD can pave new road for drug development.
Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
A look into the traits that hiring managers of pharma companies should be searching for when hiring for a leadership role.
Virtual audits proving to be beneficial post-COVID despite continuing challenges.
While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.
CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare coverage decisions.
In many plants, the full expression of therapeutic value only emerges when their components are allowed to work in concert.
Bridging the gap in data utilization and knowledge/learning management is crucial for successful drug development.
How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.
Pharma companies are now under increasing pressure, and increasingly willing, to offer a patient-centric approach. But with this increasing demand comes confusion about what patient-centered research actually is.
Patient support programs (PSPs) have an opportunity for growth and innovation.
Amid the shifting focus from primary care to specialty care, using data-driven tactics can create tailored campaigns and meaningful relationships with nurse practitioners and physician assistants.
Planning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.
Delivering value with enterprise program management.
Patient centricity and access highlight keys to success for new development.
Artificial Intelligence (AI) fueled by real-world healthcare data has yet to be fully leveraged by biopharmaceutical companies but is poised to revolutionize their business strategies.